All In Biotech

Drug Trial Radar · NCT07174336

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Dec 22, 2025

Primary completion

May 2029

Study completion May 2033

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
Pfizer
First posted
Sep 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.

Conditions

  • Breast Neoplasms
  • Neoplasm Metastasis

Interventions

  • LY4064809Drug

    Administered orally

  • PlaceboDrug

    Administered orally

  • RibociclibDrug

    Administered orally

  • PalbociclibDrug

    Administered orally

  • AbemaciclibDrug

    Administered orally

  • AnastrozoleDrug

    Administered orally

  • LetrozoleDrug

    Administered orally

  • ExemestaneDrug

    Administered orally

  • FulvestrantDrug

    Administered intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Part 1): Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR)Time frame: Baseline through disease progression or death (Estimated up to 5 years)
  2. (Part 2): Progression-Free SurvivalTime frame: Baseline to objective progression or death due to any cause (Estimated up to 5 years)

Locations

364 sites in 19 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology

    Anchorage, Alaska · Recruiting

  • Ironwood Cancer & Research Centers

    Chandler, Arizona · Recruiting

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona · Not yet recruiting

  • Mayo Clinic in Arizona - Phoenix

    Phoenix, Arizona · Not yet recruiting

  • The University of Arizona Cancer Center - North Campus

    Tucson, Arizona · Recruiting

  • Genesis Cancer and Blood Institute

    Hot Springs, Arkansas · Not yet recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • Community Cancer Institute

    Clovis, California · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • Epic Care - Emeryville

    Emeryville, California · Recruiting

  • Marin Cancer Care

    Greenbrae, California · Recruiting

  • Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine

    Irvine, California · Not yet recruiting

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Not yet recruiting

  • Kaiser Permanente Oakland

    Oakland, California · Not yet recruiting

  • Profound Research LLC

    Oceanside, California · Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center

    Orange, California · Not yet recruiting

  • Desert Regional Medical Center

    Palm Springs, California · Not yet recruiting

  • Stanford Cancer Center

    Palo Alto, California · Recruiting

  • Kaiser Permanente

    Roseville, California · Not yet recruiting

  • Kaiser Permanente

    San Francisco, California · Not yet recruiting

  • Kaiser Permanente

    Santa Clara, California · Not yet recruiting

  • UCLA Hematology/Oncology - Parkside

    Santa Monica, California · Not yet recruiting

  • Providence Medical Foundation

    Santa Rosa, California · Recruiting

  • Kaiser Permanente

    Vallejo, California · Not yet recruiting

  • Kaiser Permanente Walnut Creek

    Walnut Creek, California · Not yet recruiting

  • UCHealth Harmony

    Fort Collins, Colorado · Not yet recruiting

  • Cancer Centers of Colorado St. Mary's Regional Hospital

    Grand Junction, Colorado · Not yet recruiting

  • Banner MD Anderson Cancer Center at North Colorado Medical Center

    Greeley, Colorado · Not yet recruiting

  • Banner MD Anderson Cancer Center at McKee Medical Center

    Loveland, Colorado · Not yet recruiting

  • UConn Health

    Farmington, Connecticut · Not yet recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • AdventHealth Altamonte Springs

    Altamonte Springs, Florida · Not yet recruiting

  • Clermont Oncology Center

    Clermont, Florida · Recruiting

  • BRCR Global - Coral Springs

    Coral Springs, Florida · Not yet recruiting

  • Florida Oncology & Hematology

    Fort Myers, Florida · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Not yet recruiting

  • University of Miami Hospital and Clinics, Sylvester Cancer Center

    Miami, Florida · Not yet recruiting

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida · Recruiting

Showing 40 of 364 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.